Compounds for immunodiagnosis of prostate cancer and methods for their use
AssigneeCorixa Corporation
InventorsJiangchun Xu, Davin Dillon
Life of this patent
Estimating the term…
Abstract
Compounds and methods for diagnosing prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. The inventive polypeptides may be used to generate antibodies useful for the diagnosis and monitoring of prostate cancer. Nucleic acid sequences for preparing probes, primers, and polypeptides are also provided.
Claims22
A method for detecting prostate cancer in a patient, comprising:
- (a) contacting a biological sample obtained from the patient with a binding agent which is capable of binding to a polypeptide, the polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NOS:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-228, the complements of said nucleotide sequences and sequences that hybridize to a nucleotide sequence of SEQ ID NO:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 or 179-228 under moderately stringent hybridization conditions;
- and
- (b) detecting in the sample a protein or polypeptide that binds to the binding agent, thereby detecting prostate cancer in the patient.
A method for monitoring the progression of prostate cancer in a patient, comprising:
- (a) contacting a biological sample obtained from the patient with a binding agent that is capable of binding to a polypeptide, said polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NOS:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-228, the complements of said nucleotide sequences and sequences that hybridize to a nucleotide sequence of SEQ ID NO:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 or 179-228 under moderately stringent conditions;
- (b) determining in the sample an amount of a protein or polypeptide that binds to the binding agent;
- (c) repeating steps (a) and (b);
- and
- (d) comparing the amount of polypeptide detected in steps (b) and (c) to monitor the progression of prostate cancer in the patient.
A monoclonal antibody that binds to a polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NOS:
- 2-3, 8-29, 41-45, 47-52, 54-65, 70, 73, 74, 79, 81, 87, 90, 92, 93, 97, 103, 104, 107, 109-111, 115-160, 171, 173-175, 177, 181, 188, 191, 193, 194, 198, 203, 204, 207-228, the complements of said nucleotide sequences, and sequences that hybridize to a nucleotide sequence of SEQ ID NO:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-228 under moderately stringent conditions.
A method for detecting prostate cancer in a patient comprising:
- (a) obtaining a biological sample from the patient;
- (b) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein at least one of the oligonucleotides is specific for a DNA molecule encoding a polypeptide comprising an immunogenic portion of a prostate protein or of a variant thereof, said protein comprising an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NOS:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-228, the complements of said nucleotide sequences, and sequences that hybridize to a sequence of SEQ ID NO:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 or 179-228 under moderately stringent conditions;
- and
- (c) detecting in the sample a DNA sequence that amplifies in the presence of the oligonucleotide primers, thereby detecting prostate cancer.
A diagnostic kit comprising:
- (a) one or more monoclonal antibodies that bind to a polypeptide encoded by a DNA molecule having a nucleotide sequence selected from the group consisting of SEQ ID NOS:
- 5-7, 30-40, 46, 53, 66-69, 71, 72, 75-78, 80, 82-86, 88, 89, 91, 94-96, 98-102, 105, 106, 161-170, 179, 180, 182-187, 189, 190, 192, 195-197, 199-202, 205, 206, 225, 227 and 228, the complements of said sequences and sequences that hybridize to a nucleotide sequence of SEQ ID NO:
- 5-7, 30-40, 46, 53, 66-69, 71, 72, 75-78, 80, 82-86, 88, 89, 91, 94-96, 98-102, 105, 106, 161-170, 179, 180, 182-187, 189, 190, 192, 195-197, 199-202, 205, 206, 225, 227 or 228 under moderately stringent conditions;
- and
- (b) a detection reagent.
A diagnostic kit comprising at least two oligonucleotide primers, at least one of the oligonucleotide primers being specific for a DNA molecule encoding a polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, said protein comprising an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NOS:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-228, the complements of said nucleotide sequences and sequences that hybridize to a nucleotide sequence of SEQ ID NO:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 or 179-228 under moderately stringent conditions.
A method for detecting prostate cancer in a patient, comprising:
- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with an oligonucleotide probe specific for a DNA molecule encoding a polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, said protein comprising an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ IDNOS:
- 2-3,5-107, 109-111, 115-171, 173-175, 177 and 179-228, the complements of said nucleotide sequences and sequences that hybridize to a nucleotide sequence of SEQ ID NO:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-228 under moderately stringent conditions;
- and
- (c) detecting in the sample a DNA sequence that hybridizes to the oligonucleotide probe, thereby detecting prostate cancer in the patient.
A diagnostic kit comprising an oligonucleotide probe specific for a DNA molecule encoding a polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, said protein comprising an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NOS:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-228, the complements of said nucleotide sequences and sequences that hybridize to a nucleotide sequence of SEQ ID NO:
- 2-3, 5-107, 109-111, 115-171, 173-175, 177 or 179-228 under moderately stringent conditions.
Dependencies are inferred from the claim text.